Bristol’s Breast Cancer Treatment Ixempra Gets FDA Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
Ixempra, part of a new class of antineoplastic chemotherapy agents, is approved as both a monotherapy and in combination with capecitabine.